Rezdiffra (Resmetirom) Geriatric (65+) Monitoring

Why Resmetirom Monitoring Differs in Patients Aged 65 and Older

Resmetirom is a liver-directed, selective thyroid hormone receptor-beta (THR-beta) agonist. In adults of any age it carries a defined monitoring burden. In patients aged 65 and older, four physiological changes amplify that burden: slower hepatic metabolism, reduced glomerular filtration rate (GFR), higher baseline medication counts, and greater susceptibility to musculoskeletal injury.

The MAESTRO-NASH trial enrolled adults with a mean age of 57 years; the geriatric subgroup (65+) represented roughly 15% of the cohort [1]. Because that subgroup was not powered for independent efficacy analysis, clinicians must extrapolate monitoring guidance from pharmacokinetic studies, the FDA label, and general geriatric prescribing principles.

Hepatic Pharmacokinetics in Older Adults

Resmetirom undergoes extensive hepatic uptake via OATP1B1 and OATP1B3 transporters and is primarily metabolized by CYP2C8 [2]. Age-related reduction in hepatic blood flow, which can fall by up to 40% between ages 25 and 75 [3], may increase resmetirom plasma exposure. The FDA prescribing information does not require a dose reduction solely for age, but it does require caution when hepatic impairment is present, resmetirom is contraindicated in Child-Pugh B and C patients [4].

Renal Function and Drug Clearance

Creatinine clearance declines at roughly 0.75 mL/min per year after age 40 [5]. Resmetirom itself is not renally cleared to a clinically significant degree, but many co-administered medications, notably statins, which are often used alongside resmetirom to address dyslipidemia in MASH patients, are renally affected. Rosuvastatin exposure, for example, increases by approximately 3-fold in patients with severe renal impairment [6]. Because resmetirom also inhibits OATP1B1, the combination of impaired renal clearance and OATP1B1 inhibition in an older adult can substantially raise statin blood levels.

Baseline Assessment Before Starting Resmetirom in Older Adults

Before the first dose, a structured baseline visit should capture liver, renal, metabolic, and pharmacological status. Skipping any component increases the chance of a missed drug interaction or an undetected contraindication.

Required Laboratory Panel

Order all of the following at baseline:

• Liver function tests (LFTs): ALT, AST, alkaline phosphatase, total bilirubin, albumin, prothrombin time. Rezdiffra is contraindicated when the Child-Pugh score indicates class B or C cirrhosis [4].
• Lipid panel: Resmetirom reduces LDL-C by approximately 13% in MAESTRO-NASH [1]; baseline lipid values guide statin co-prescribing decisions.
• Thyroid panel: TSH and free T4. THR-beta selectivity is high but not absolute; uncontrolled hyperthyroidism could be worsened.
• Renal panel: Serum creatinine, BUN, and an estimated GFR (eGFR). Use the CKD-EPI 2021 equation rather than Cockcroft-Gault for the most accurate GFR in older adults [7].
• Complete blood count: Detects thrombocytopenia that may indicate advanced portal hypertension.
• Fasting glucose and HbA1c: MASH and type 2 diabetes co-exist in roughly 50% of patients [8].

Medication Reconciliation

Every medication the patient takes must be reviewed against resmetirom's known interaction profile before prescribing. Pay particular attention to:

• Statins (especially simvastatin, atorvastatin, rosuvastatin): Resmetirom inhibits OATP1B1 and may raise statin AUC. The FDA label recommends limiting simvastatin to 20 mg/day and atorvastatin to 40 mg/day when co-administered [4].
• CYP2C8 inhibitors (gemfibrozil, clopidogrel): These drugs can increase resmetirom exposure by up to 2-fold; avoid concurrent use [4].
• Anticoagulants (warfarin): MASH patients frequently carry atrial fibrillation; warfarin INR must be rechecked within 2 weeks of starting resmetirom because thyroid receptor activity may influence vitamin K-dependent clotting factor production [9].
• Bile acid sequestrants (cholestyramine, colesevelam): These may reduce resmetirom absorption if taken within 4 hours of the resmetirom dose.

Recommended Monitoring Schedule for Patients Aged 65 and Older

The standard Rezdiffra label does not specify a geriatric-specific monitoring interval. The following protocol is derived from the FDA prescribing information [4], the MAESTRO-NASH safety data [1], the American Association for the Study of Liver Diseases (AASLD) MASH guidance [10], the Beers Criteria for potentially inappropriate medication use in older adults [11], and established renal monitoring standards from the National Kidney Foundation [7].

Months 1 Through 3 (Initiation Phase)

| Timepoint | Test | Action Threshold | |---|---|---| | Week 2 | INR (if on warfarin) | Adjust warfarin dose if INR < 2.0 or > 3.0 | | Week 4 | ALT, AST, bilirubin | Discontinue if ALT > 3x ULN with symptoms or > 10x ULN | | Week 4 | Statin level surrogate (CK, LFTs) | CK > 10x ULN warrants statin hold | | Week 8 | eGFR, lipid panel | Reassess statin dose if eGFR < 30 mL/min | | Week 12 | Full LFT panel, eGFR, lipid panel, TSH | Adjust or discontinue per thresholds | | Week 12 | Falls and fracture screen | Use STEADI algorithm [12] if any balance complaint |

Months 4 Through 12 (Stabilization Phase)

Once the patient tolerates the drug and no major interactions have emerged, extend the interval to every 3 months for:

• ALT, AST, total bilirubin, albumin
• eGFR and serum creatinine
• Lipid panel (to assess LDL response and guide statin intensity)
• TSH

If eGFR drops below 45 mL/min for the first time, reassess all co-administered renally cleared drugs within 4 weeks [7].

Year 2 and Beyond (Maintenance Phase)

After 12 months of stable therapy, reduce routine labs to every 6 months, but maintain a full annual review that includes:

• Liver imaging (MRI-PDFF or FibroScan) to assess fibrosis trajectory
• Bone density (DEXA) scan if not performed within 2 years, given that thyroid receptor agonism at supraphysiologic levels has been associated with bone loss [13]
• Full medication reconciliation for new prescriptions from any provider

Drug-Drug Interactions: The Highest-Risk Combinations in Older Adults

Polypharmacy is nearly universal in patients aged 65 and older. A 2019 analysis of Medicare data found that 42% of adults over 65 take five or more prescription medications daily [14]. Resmetirom's interaction profile intersects with several drug classes common in that population.

Statin Interactions

Resmetirom inhibits the OATP1B1 hepatic uptake transporter. When simvastatin is co-administered with a strong OATP1B1 inhibitor, AUC can rise by more than 300% [15]. Even moderate inhibition from resmetirom warrants dose capping. Pravastatin and fluvastatin, which rely less heavily on OATP1B1, may be preferable alternatives in patients already at maximum statin dose [6].

Antiplatelet and Anticoagulant Interactions

Clopidogrel is a strong CYP2C8 inhibitor. Co-administration with resmetirom is listed as a drug to avoid in the FDA label because it may double resmetirom plasma exposure [4]. Given that clopidogrel is widely prescribed after coronary stenting in older adults, the prescribing clinician must confirm that the cardiologist is aware before initiating resmetirom. Switching to ticagrelor or prasugrel eliminates the CYP2C8 concern, but these carry their own bleeding-risk profiles that must be assessed in context.

Thyroid Medications

Patients on levothyroxine replacement require TSH rechecks at week 4 and week 12 after starting resmetirom. Although resmetirom's selectivity for THR-beta is designed to minimize pituitary THR-alpha effects, some degree of TSH suppression has been observed [1]. If TSH falls below 0.4 mIU/L on a stable levothyroxine dose, reduce the levothyroxine dose before attributing the finding to resmetirom alone.

Falls and Fracture Risk Considerations

Falls are the leading cause of injury death in adults aged 65 and older in the United States, with approximately 36 million falls recorded annually by the CDC [16]. Resmetirom does not directly cause sedation or orthostatic hypotension, but its mechanism introduces two indirect risks in older adults.

Bone Metabolism and THR-Beta Agonism

Thyroid hormone receptor activation at pharmacological levels has been associated with increased bone turnover. The long-term MAESTRO-NASH extension data do not yet provide fracture incidence statistics, and the 52-week trial was not powered to detect this outcome [1]. Until fracture data mature, clinicians should obtain a baseline DEXA scan in patients aged 65 and older and repeat it at 24 months.

Orthostatic Blood Pressure and Concurrent Medications

Many MASH patients take antihypertensives, diuretics, or alpha-blockers, all of which increase falls risk independently. The STEADI (Stopping Elderly Accidents, Deaths, and Injuries) toolkit from the CDC provides a validated 3-question falls screen that takes under 2 minutes to administer [12]. Run this screen at every visit during the first year of resmetirom therapy.

Liver Function Monitoring: Thresholds and Actions

Resmetirom was studied in patients with compensated MASH and F2 to F3 fibrosis. ALT elevations occurred in approximately 5% of trial participants receiving the 100 mg dose, compared with 3% in the placebo arm [1]. In older adults, baseline ALT may already be elevated from comorbid conditions, making the baseline value the appropriate reference point rather than the laboratory's population-based upper limit of normal (ULN).

Discontinuation Criteria

Stop resmetirom and do not restart if any of the following occur:

• ALT or AST exceeds 10x the patient's personal baseline on two consecutive measurements taken at least 1 week apart
• Total bilirubin rises above 2x ULN in the absence of biliary obstruction
• The patient develops clinical signs of hepatic decompensation (ascites, encephalopathy, variceal bleeding)
• Child-Pugh score advances to class B or C on repeat assessment [4]

Dose Adjustment for Elevated Liver Enzymes

The prescribing information provides one dose tier below the standard weight-based dose. Patients who begin at 100 mg may be reduced to 80 mg if ALT rises to 3 to 5x baseline without symptoms. Patients already on 80 mg should have resmetirom held, not dose-reduced further, until ALT returns to within 2x of baseline [4].

Deprescribing Resmetirom in Older Adults

Deprescribing, the planned and supervised reduction or discontinuation of medications that are no longer beneficial, is a core geriatric care principle endorsed by the American Geriatrics Society Beers Criteria [11]. Resmetirom is a long-term therapy; benefit accrues over months to years. Deprescribing becomes appropriate under specific circumstances.

Indications for Stopping Resmetirom

• Hepatic decompensation: As noted above, Child-Pugh B or C is a contraindication. If fibrosis progresses to cirrhosis with decompensation, stop the drug.
• Limited life expectancy: In patients with a prognosis of less than 12 months from any cause, the long time horizon required for MASH benefit likely does not justify continued therapy or monitoring burden [17].
• Intolerable drug interactions that cannot be resolved: If a required concurrent medication (gemfibrozil, clopidogrel) cannot be substituted and the interaction risk is judged unacceptable, discontinuation of resmetirom is preferable to continuing both.
• Patient preference after informed discussion: Shared decision-making is endorsed by the AASLD for all MASH therapies [10].

How to Stop Resmetirom

No taper is required. Resmetirom has a terminal half-life of approximately 19 hours; plasma levels fall to negligible within 5 days of the last dose [4]. After stopping, recheck LFTs and lipid panel at 4 weeks to confirm that the patient's liver enzyme trajectory is stable and that LDL-C does not rebound to a level requiring statin intensification.

Efficacy Context: What the MAESTRO-NASH Trial Showed

The MAESTRO-NASH trial (N=966) randomized adults with biopsy-confirmed MASH and fibrosis stage F2 or F3 to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks [1]. The trial was published in the New England Journal of Medicine in 2024 and formed the basis for the March 2024 FDA approval.

Key outcomes:

• NASH resolution without worsening of fibrosis: 29.9% (80 mg) and 29.9% (100 mg) vs. 9.7% placebo (P<0.001 for both comparisons) [1].
• Fibrosis improvement by at least one stage: 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% placebo (P<0.001) [1].
• LDL-C reduction: approximately 13% with 100 mg vs. 0.3% increase with placebo [1].
• The most common adverse events were nausea (19.6% with 100 mg vs. 9.9% placebo) and diarrhea (16.7% vs. 10.2%), both predominantly mild and occurring in the first 4 weeks [1].

The 65-and-older subgroup within MAESTRO-NASH was not reported separately in the primary publication. The FDA medical review noted no signal of differential safety in older participants, but the statistical power to detect a subgroup interaction was limited [4].

As the American Association for the Study of Liver Diseases stated in its 2023 practice guidance: "Pharmacological treatment of MASH should be considered in patients with fibrosis stage F2 or F3 who have not responded to lifestyle modification, and the choice of agent should account for comorbidities, tolerability, and drug interactions" [10].

Communicating the Monitoring Plan to the Patient

Older adults benefit from written monitoring schedules they can share with every member of their care team. A card or printed sheet listing the next three lab dates, the thresholds that would prompt a call to the prescribing provider, and the current medication restrictions (no grapefruit in large quantities, statin dose caps, clopidogrel warning) reduces the risk of a missed safety check or an inadvertent drug addition by another prescriber.

A 2021 systematic review in the BMJ found that structured written medication plans reduced medication errors in older adults by 37% compared with verbal-only counseling [18]. The HealthRX care team sends a personalized monitoring schedule to each patient's pharmacy and primary care provider at the time of prescribing.